L26/P-675 Mitochondrial DNA segregation in early embryos: implications for preimplantation genetic testing for mitochondrial disorders
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.1005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von N. Castelluccio und 12 weiteren Autor:innen.
Abstract (Originalsprache)
Study question Is mitochondrial DNA (mtDNA) heteroplasmy concordant across early embryonic stages and lineages? Summary answer Concordance in heteroplasmy levels was established in human and mouse embryos, supporting the feasibility and reliability of preimplantation genetic testing for mitochondrial disorders (PGT-MT). What is known already The intricate dynamics of mtDNA segregation and inheritance patterns remain poorly understood, particularly in the context of heteroplasmy, defined as the coexistence of multiple mtDNA variants within a cell. This variability complicates the prediction of mtDNA transmission in oocytes and embryos, making genetic counselling for women carrying pathogenic mtDNA mutations particularly challenging. PGT-MT aims to reduce the risk of disease transmission by selecting embryos with low mtDNA heteroplasmy levels. However, the reliability of the technique depends on the biopsy accurately reflecting the embryo’s mtDNA mutation load and heteroplasmy remaining stable across different developmental stages. Study design, size, duration Heteroplasmy was analysed across preimplantation development in a mouse model carrying the m.5024C>T mutation (mt-Ta) and in human blastocysts from two carriers of the m.3243A>G pathogenic variant (MT-TL1), associated with MELAS syndrome. Mouse samples included oocytes, polar bodies, blastomeres from two- and eight-cell embryos, and trophectoderm (TE) and inner cell mass (ICM) from blastocysts. Human analyses focused on TE and ICM from surplus blastocysts donated following PGT-MT, with postnatal follow-up available for two single-embryo transfers. Participants/materials, setting, methods Heteroplasmic mouse embryos were generated by mating m.5024C>T females with wild-type males. Human blastocysts were obtained from two m.3243A>G carriers undergoing PGT-MT at our centre, who showed peripheral blood mutation loads of 27% and 34%, respectively. Single-cell dissociation or lineage biopsies were performed, and mtDNA heteroplasmy and copy number were quantified using digital PCR (dPCR) and targeted next generation sequencing (NGS). Assays were validated using synthetic templates with known mutation loads. Main results and the role of chance In mouse embryos, mutation levels in both blastomere and TE biopsies strongly correlated with whole-embryo heteroplasmy (R²=0.90 and R²=0.92, respectively; n = 56). Following single-cell dissociation, no significant variation in heteroplasmy levels was observed across blastomeres within individual embryos (n = 160 from 20 eight-cell embryos; p=0.74). Similarly, strong concordance was observed between ICM and TE in blastocysts (R²=0.93; n = 33). In contrast, oocytes and their corresponding polar bodies (n = 23) displayed moderate correlation (R²=0.46). Mean mtDNA copy number per cell decreased progressively from oocytes to cleavage-stage embryos and blastocysts, with polar bodies containing minimal mtDNA. In human, patient A underwent four PGT-MT cycles, yielding 18 blastocysts. Two single-embryo transfers with heteroplasmy of 15.5% and 12.8% resulted in the birth of healthy male children, with postnatal heteroplasmy consistent with PGT biopsy results (15% and 18%, respectively). The remaining embryos ranged from 19% to 57%. Patient B underwent two cycles, producing 13 blastocysts; one embryo showed low heteroplasmy (3%), with no transfer performed to date, while others ranged from 31% to 63%. Preliminary analysis of donated surplus blastocysts (n = 12) showed strong agreement between ICM and TE (R²=0.95) and no statistical significant difference compared to the original PGT biopsy results (p>0.05 in all embryos). Limitations, reasons for caution This study analysed a limited number of human embryos and carriers and focused on heteroplasmic point mutations in mtDNA tRNA genes. Ongoing studies including additional mtDNA variants and extended postnatal follow-up will further strengthen conclusions on long-term heteroplasmy stability. Wider implications of the findings These findings support the biological validity and clinical reliability of PGT-MT by demonstrating stable mtDNA heteroplasmy across preimplantation stages and embryonic lineages. Ongoing follow-up of children and future studies extending to peri-implantation stages will further elucidate post-implantation mtDNA segregation dynamics after the resumption of mtDNA replication. Trial registration number No
Zitieren
APA
Castelluccio, N., Prycker, Y. D., Rybouchkin, A., Gleerup, D., Jalali, F., Croo, I. D., Gheselle, S. D., Symoens, S., Janssens, S., Menten, B., Stoop, D., Spiegelaere, W. D., & Heindryckx, B. (2026). L26/P-675 Mitochondrial DNA segregation in early embryos: implications for preimplantation genetic testing for mitochondrial disorders. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.1005
Vancouver
Castelluccio N, Prycker YD, Rybouchkin A, Gleerup D, Jalali F, Croo ID, et al. L26/P-675 Mitochondrial DNA segregation in early embryos: implications for preimplantation genetic testing for mitochondrial disorders. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.1005
BibTeX
@article{Castelluccio2026,
author = {Castelluccio, N. and Prycker, Y. De and Rybouchkin, A. and Gleerup, D. and Jalali, F. and Croo, I. De and Gheselle, S. De and Symoens, S. and Janssens, S. and Menten, B. and Stoop, D. and Spiegelaere, W. De and Heindryckx, B.},
title = {L26/P-675 Mitochondrial DNA segregation in early embryos: implications for preimplantation genetic testing for mitochondrial disorders},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.1005}
}
EUVIMED